34.11
-1.14 (-3.23%)
| Previous Close | 35.25 |
| Open | 35.63 |
| Volume | 2,104,877 |
| Avg. Volume (3M) | 1,502,319 |
| Market Cap | 4,081,500,416 |
| Price / Sales | 70.65 |
| Price / Book | 60.31 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Operating Margin (TTM) | -9,856.30% |
| Diluted EPS (TTM) | -5.29 |
| Quarterly Revenue Growth (YOY) | 89.10% |
| Total Debt/Equity (MRQ) | 727.94% |
| Current Ratio (MRQ) | 5.99 |
| Operating Cash Flow (TTM) | -398.00 M |
| Levered Free Cash Flow (TTM) | -241.41 M |
| Return on Assets (TTM) | -34.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Cytokinetics, Incorporated | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -2.5 |
| Price Volatility | 4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.80 |
|
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.72% |
| % Held by Institutions | 119.58% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 96.00 (Stifel, 181.44%) | Buy |
| Median | 79.00 (131.60%) | |
| Low | 71.00 (Barclays, 108.15%) | Buy |
| Average | 80.17 (135.03%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 49.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 03 Sep 2025 | 71.00 (108.15%) | Buy | 49.99 |
| Evercore ISI Group | 03 Sep 2025 | 80.00 (134.54%) | Buy | 49.99 |
| Citigroup | 02 Sep 2025 | 84.00 (146.26%) | Buy | 49.62 |
| 08 Aug 2025 | 77.00 (125.74%) | Buy | 34.11 | |
| JMP Securities | 02 Sep 2025 | 78.00 (128.67%) | Buy | 49.62 |
| Needham | 02 Sep 2025 | 72.00 (111.08%) | Buy | 49.62 |
| Stifel | 02 Sep 2025 | 96.00 (181.44%) | Buy | 49.62 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MALIK FADY IBRAHAM | - | 51.50 | -2,000 | -103,000 |
| Aggregate Net Quantity | -2,000 | |||
| Aggregate Net Value ($) | -103,000 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 51.50 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MALIK FADY IBRAHAM | Officer | 09 Sep 2025 | Sell (-) | 2,000 | 51.50 | 103,000 |
| MALIK FADY IBRAHAM | Officer | 09 Sep 2025 | Option execute | 2,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |